WO2000027375A3 - Idarubicin plus melphalan conditioning regimen - Google Patents

Idarubicin plus melphalan conditioning regimen Download PDF

Info

Publication number
WO2000027375A3
WO2000027375A3 PCT/EP1998/007214 EP9807214W WO0027375A3 WO 2000027375 A3 WO2000027375 A3 WO 2000027375A3 EP 9807214 W EP9807214 W EP 9807214W WO 0027375 A3 WO0027375 A3 WO 0027375A3
Authority
WO
WIPO (PCT)
Prior art keywords
idarubicin
conditioning regimen
melphalan
regimen
plus melphalan
Prior art date
Application number
PCT/EP1998/007214
Other languages
French (fr)
Other versions
WO2000027375A2 (en
Inventor
Giovanni Martinelli
Marcello Riggi
Original Assignee
Pharmacia & Upjohn Spa
Giovanni Martinelli
Marcello Riggi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Spa, Giovanni Martinelli, Marcello Riggi filed Critical Pharmacia & Upjohn Spa
Priority to PCT/EP1998/007214 priority Critical patent/WO2000027375A2/en
Publication of WO2000027375A2 publication Critical patent/WO2000027375A2/en
Publication of WO2000027375A3 publication Critical patent/WO2000027375A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

There is described the use of idarubicin at dosages of from 12 to 17 mg/m2 days 1-3 i.v. as continuous infusion, followed by Melphalan, 180 mg/m2, day 5, as a conditioning regimen for the treatment of cancers responsive to idarubicin such as multiple myeloma (MM), non Hodgkin lymphoma (NHL) and Hodgkin disease (HD). The regimen of the present invention is of great advantage because transplant is done at day +7.
PCT/EP1998/007214 1998-11-09 1998-11-09 Idarubicin plus melphalan conditioning regimen WO2000027375A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/EP1998/007214 WO2000027375A2 (en) 1998-11-09 1998-11-09 Idarubicin plus melphalan conditioning regimen

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP1998/007214 WO2000027375A2 (en) 1998-11-09 1998-11-09 Idarubicin plus melphalan conditioning regimen

Publications (2)

Publication Number Publication Date
WO2000027375A2 WO2000027375A2 (en) 2000-05-18
WO2000027375A3 true WO2000027375A3 (en) 2007-06-07

Family

ID=8167125

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/007214 WO2000027375A2 (en) 1998-11-09 1998-11-09 Idarubicin plus melphalan conditioning regimen

Country Status (1)

Country Link
WO (1) WO2000027375A2 (en)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HEYLL A ET AL: "Hochdosischemotherapie bei Patienten mit multiplen Myelomen.", SCHWEIZERISCHE RUNDSCHAU FUR MEDIZIN PRAXIS, (1998 JUN 24) 87 (25-26) 879-83., XP002109726 *
HEYLL A ET AL: "Idarubicin, melphalan and cyclophosphamide: an intensified high-dose regimen for the treatment of myeloma patients.", LEUKEMIA, (1997 DEC) 11 SUPPL 5 S32-4., XP002109727 *

Also Published As

Publication number Publication date
WO2000027375A2 (en) 2000-05-18

Similar Documents

Publication Publication Date Title
CA2274149A1 (en) Peptides and compounds that bind to a receptor
MY113497A (en) Peptides and compounds that bind to a receptor
MX9709315A (en) Peptides and compounds that bind to a thrombopoietin receptor.
EP0760658A4 (en) Compounds for inhibiting osteoclast-mediated bone resorption
BG103805A (en) Trifluoromethylalkylaminotriazolopyrimidines with fungicidal effect
IL122406A0 (en) Bacterial inhibition with an oligosaccharide compound
BG102259A (en) Compostions with controlled paroxetine release
GR3036714T3 (en) Fungicidal trifluorophenyl-triazolopyrimidines
AU1632297A (en) Treatment of ocular inflammation by blockage of cell adhesion molecules
MX9503529A (en) Glycinamide derivatives, process for their preparation and medicaments containing them.
EP0742010A3 (en) Benzoquinolin-3-ones to inhibit bone loss
BG101892A (en) Sugar-modified cytostatics
AU8974298A (en) 1,4,7,10-tetraazabicyclo{8.2.2}tetradecan-2-one, a process for the preparation thereof and the use thereof for the preparation of tetraazamacrocycles
ES2088771A1 (en) Method for improving breeding activity of boars by using feed for the breeding boars
BG103872A (en) Glycoconjugates of 20(s)-camptotecin
CA2286296A1 (en) Inhibitors for urokinase receptor
AU8631698A (en) A process for the preparation of tetraazamacrocycles
EP0868197A4 (en)
WO2000027375A3 (en) Idarubicin plus melphalan conditioning regimen
AU4925200A (en) Oral composition containing perlite
BG101794A (en) Method for the preparation of trihydrate of (2r, 3s)-3-benzoylamino-2-hydroxy-3-phenylpropionate of 4, 10-diacetoxy-2 alpha-benzoyloxy-5 beta, 20-epoxy-1,7 beta -dihydroxy-9-oco-tax-11-en-13 alpha-yl
AU3166295A (en) Imidazopyridine-azolidinones
CA2159330A1 (en) Inhibition of leukocyte adhesion
ES2170377T3 (en) COMPOSITION CONTAINING QUITOSANA.
BG103779A (en) Crystallohydrate sodium salt of (e)-4,6-dichloro-3-(2-oxo-1-phenylpyrrolidine-3-ilidenmethyl)-1h-i ndole-2-carboxylic acid

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA US

NENP Non-entry into the national phase

Ref country code: CA